SCHEMBL6320173

SCHEMBL6320173

O=C(O)c1ccccc1-c1ccc(CN(C(=O)c2ccc(Cl)cc2Cl)C(Cc2ccccc2)C(=O)O)o1

nearest known ligand 0.57

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.41
LDHA P00338 1/20 0.39
LDHB P07195 1/20 0.39
HAO1 Q9UJM8 1/20 0.39
PTGER1 P34995 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324869 0.93 PPARA (0.42) PPARA
SCHEMBL6324874 0.93 PPARA (0.42) PPARA
SCHEMBL6317474 0.92 PPARA (0.43) PPARA
SCHEMBL6317480 0.92 PPARA (0.43) PPARA
SCHEMBL6322243 0.89 PPARA (0.39) PPARA
SCHEMBL6322235 0.89 PPARA (0.39) PPARA
SCHEMBL6317466 0.88 LMNA (0.42) PPARA
SCHEMBL6317461 0.88 LMNA (0.42) PPARA
SCHEMBL6325311 0.87 TP53 (0.46) PPARALDHALDHBHAO1
SCHEMBL6325308 0.87 TP53 (0.46) PPARALDHALDHBHAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887877-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-05-03 US claimed
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections SHIRE BIOCHEM INC. (CA) 2003-12-11 US claimed
US-6887877-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-05-03 US disclosed
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections SHIRE BIOCHEM INC. (CA) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections HAVCR2, ZC3HAV1, MAVS PPARA 2311/4885LDHA 2779/4885LDHB 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.